Skip to content

Effects of Telmisartan on Early Markers of Atherosclerosis in Hypertension with and without Hyperlipidemia - ND

Effects of Telmisartan on Early Markers of Atherosclerosis in Hypertension with and without Hyperlipidemia - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-004853-38-IT
Enrollment
Unknown
Registered
2007-05-16
Start date
2006-11-02
Completion date
Unknown
Last updated
2014-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperlipidemia MedDRA version: 6.1 Level: PT Classification code 10020772

Interventions

Trade Name: MICARDIS*28CPR 40MG Pharmaceutical Form: Tablet INN or Proposed INN: Telmisartan CAS Number: 144701-48-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number:

Sponsors

AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: age 18-80 BMI 140 e 90 mmHg e 250 mg/dl Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: renal failure (CK>1.8 mg/dl) epatic failure secondary hypertension secondary hyperlipidemia congestive heart failure

Design outcomes

Primary

MeasureTime frame
Main Objective: to evaluate the degree of the expression and activity of some molecules likely regulated by the the activation of the RAS system and playing a key role in the early atherosclerosis;Secondary Objective: to evaluate the effect of the AT-1 blocker telmisartan in modulating these molecules in patients with hypercholesterolemia, particularly in terms of response to treatment;Primary end point(s): to evaluate the degree of the expression and activity of some molecules likely regulated by the the activation of the RAS system and playing a key role in the early atherosclerosis

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026